University of Tennessee Graduate School of Medicine
Trial Pipeline
Improved Outcomes With Pre-Procedure Shockwave IVL of Common Femoral Artery Access Site Prior to Large Bore Access and Pre-Closure
NCT07205068
Efficacy of Perioperative Opioid Sparing Techniques on Time to Initiation of Chemotherapy
NCT07153614
Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclampsia
NCT06802861
Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators
NCT07133880
Dysregulation of Whole-body Metabolism in Ovarian Cancer: A Longitudinal Study
NCT06800105
Personalized Post-Operative Pain Management
NCT06669650
Assessing Whole-body Metabolism in Gynecologic Cancers in Response to a Single Chemotherapy Cycle and/ or Immunotherapy
NCT07393633
Acute Effects of Maternal Exercise and the Growth Restricted Pregnancy
NCT06039319
COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers
NCT02291016
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 2 |
What the Pipeline for University of Tennessee Graduate School of Medicine Shows
According to the ClinicalTrials.gov registry, University of Tennessee Graduate School of Medicine is linked to 9 US clinical trials across every stage of research activity. Of those, 5 studies are currently recruiting — about 56% of the sponsor's indexed portfolio — and 3 are already marked complete, representing roughly 33% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for University of Tennessee Graduate School of Medicine reports 2 late-stage studies (Phase 3 and Phase 4 combined) and 0 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for University of Tennessee Graduate School of Medicine is Fetal Growth Complications with 1 linked trial, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.